Health minister orders inquiry into unapproved peptides
Mark Butler has ordered an inquiry into peptides amid concerns about unsafe online prescribing practices and an alarming surge in hospital visits linked to the substances.
Health Minister Mark Butler has initiated an inquiry into the prescription and usage of unapproved peptides, following a surge in popularity on social media platforms where they are often touted as miracle solutions for weight-loss, anti-aging and muscle growth. These peptides, which are short chains of amino acids, are short chains of amino acids that make up proteins in the body. While some approved peptide-based medicines exist, many sold online are unregulated, raising concerns about their safety and efficacy.
Butler expressed deep concern over the escalating reports of unapproved peptides being prescribed and delivered via telehealth and one-stop-shop-style dispensaries, highlighting the potential health risks for Australian consumers. Special Envoy for Men's Health, Dan Repacholi, warned that social media can be filled with individuals promoting these substances, without acknowledging the inherent risks, particularly for young individuals who may be misled by such claims.
The Therapeutic Goods Administration (TGA) has observed a rise in the importation and advertising of these unapproved peptide products in Australia, emphasizing that the substances being promoted online have not undergone rigorous checks for quality, safety, or efficacy, potentially posing serious health threats. NSW Health data revealed a sharp increase in hospital visits linked to unapproved peptides, with cases soaring from five in July 2025 to 217 in September 2025.
Furthermore, a coroner recently determined that Australian actor Richard Norton's death in 2025 was triggered by his injection of unapproved peptides, marking it as the first confirmed fatality in Australia attributed to these substances.
The parliamentary inquiry into the safety and quality of online prescribing practices for peptides is set to commence consultation hearings this month, with a final report anticipated in mid-2027. The inquiry aims to address the growing concerns over the misuse and potential hazards associated with the unregulated sale and prescription of peptides.
Rewritten by urgent.news; may contain errors — check the original.